
Sign up to save your podcasts
Or
Today's episode features the CEO of Tome Biosciences, Rahul Kakkar, alongside John Finn, CSO of Tome. They are joined by Jorge Conde, general partner at a16z Bio + Health.
Together, the three of them discuss the technology underlying Tome's work, known as PASTE, a genome editing technique. They also dive deep into how this technology could be applied to help patients, making cell therapy more accessible for more people.
Editorial note: We mistakenly identified Rahul Kakkar and John Finn as the co-founders of Tome Biosciences. In reality, Rahul serves as the CEO, and John is the CSO of Tome. The actual co-founders of Tome Biosciences are Jonathan Gootenberg and Omar Abudayyeh.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
4.6
143143 ratings
Today's episode features the CEO of Tome Biosciences, Rahul Kakkar, alongside John Finn, CSO of Tome. They are joined by Jorge Conde, general partner at a16z Bio + Health.
Together, the three of them discuss the technology underlying Tome's work, known as PASTE, a genome editing technique. They also dive deep into how this technology could be applied to help patients, making cell therapy more accessible for more people.
Editorial note: We mistakenly identified Rahul Kakkar and John Finn as the co-founders of Tome Biosciences. In reality, Rahul serves as the CEO, and John is the CSO of Tome. The actual co-founders of Tome Biosciences are Jonathan Gootenberg and Omar Abudayyeh.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
1,288 Listeners
530 Listeners
1,088 Listeners
2,330 Listeners
124 Listeners
325 Listeners
104 Listeners
86 Listeners
33 Listeners
25 Listeners
20 Listeners
155 Listeners
59 Listeners
58 Listeners
133 Listeners
125 Listeners
510 Listeners
33 Listeners